Advanced Research in Imaging-Guided Cancer Therapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 1 July 2025 | Viewed by 3463

Special Issue Editors


E-Mail Website
Guest Editor
Facoltà di Medicina e Chirurgia, Università degli Studi di Firenze, Florence, Italy
Interests: nuclear medicine; PET imaging; neuroendocrine tumors; PRRT; neurodegenerative diseases

E-Mail Website
Guest Editor
Department of Nuclear Medicine, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France
Interests: nuclear medicine; PET imaging; neuroendocrine tumors; PRRT; paraganglioma; pheochromocytoma; thyroid medullary carcinoma; infection
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We welcome you to contribute to this Special Issue dedicated to "Advance Research in Imaging-Guided Cancer Therapy". Imaging-guided cancer therapy represents a paradigm shift in oncology, enabling the precise visualization of tumors and their microenvironment, thus empowering clinicians to tailor treatment strategies with unprecedented accuracy. From early detection and diagnosis to treatment planning, monitoring, and response assessment, imaging techniques play a pivotal role at every stage of the cancer care continuum. Moreover, by integrating imaging modalities with therapeutic interventions, such as targeted drug delivery, radiotherapy, and minimally invasive procedures, researchers are ushering in a new era of personalized, precision medicine.

This Special Issue aims to showcase the latest advancements in imaging-guided cancer therapy, highlighting groundbreaking research and technological innovations that promise to shape the future of oncology. Through a collection of original research articles and reviews, we aim to provide a comprehensive overview of the current state-of-the-art in this rapidly evolving field. Topics of interest include, but are not limited to, the following:

- Novel imaging techniques for cancer detection, characterization, and staging;

- Image-guided interventions for minimally invasive cancer treatment;

- Theranostic agents and multimodal imaging approaches;

- Artificial intelligence and machine learning in imaging analysis and interpretation;

- Image-based biomarkers for treatment response prediction and prognosis;

- Translation of imaging-guided therapies from bench to bedside;

- Challenges and opportunities in clinical implementation and validation;

- Ethical, regulatory, and socioeconomic considerations in imaging-guided cancer care.

We invite researchers to contribute their original research and insights to this Special Issue, fostering interdisciplinary collaboration and knowledge exchange in the pursuit of improved outcomes for cancer patients.

We look forward to receiving your contributions.

Dr. Valentina Berti
Prof. Dr. Alessio Imperiale
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • imaging-guided therapies
  • theranostic
  • cancer
  • PET imaging
  • nuclear medicine
  • nuclear oncology
  • precision medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

14 pages, 1873 KiB  
Article
The Impact of Socioeconomic Status and Comorbidities on Non-Melanoma Skin Cancer Recurrence After Image-Guided Superficial Radiation Therapy
by Liqiao Ma, Michael Digby, Kevin Wright, Marguerite A. Germain, Erin M. McClure, Francisca Kartono, Syed Rahman, Scott D. Friedman, Candace Osborne and Alpesh Desai
Cancers 2024, 16(23), 4037; https://doi.org/10.3390/cancers16234037 - 1 Dec 2024
Viewed by 2366
Abstract
Background: Non-melanoma skin cancers (NMSCs) are the most common cancers in the United States. Image-guided superficial radiation therapy (IGSRT) is an effective treatment for NMSCs. Patient comorbidities and socioeconomic status (SES) are known contributors to health disparities. However, the impact of comorbidities or [...] Read more.
Background: Non-melanoma skin cancers (NMSCs) are the most common cancers in the United States. Image-guided superficial radiation therapy (IGSRT) is an effective treatment for NMSCs. Patient comorbidities and socioeconomic status (SES) are known contributors to health disparities. However, the impact of comorbidities or SES on the outcomes of IGSRT-treated NMSCs has not yet been studied. This study evaluated freedom from recurrence in IGSRT-treated NMSCs stratified by SES and the number of comorbidities. Methods: This large retrospective cohort study evaluated associations between SES (via Area Deprivation Index (ADI)) or comorbidity (via Charlson Comorbidity Index (CCI)) and 2-, 4-, and 6-year year freedom from recurrence in patients with IGSRT-treated NMSC (n = 19,988 lesions). Results: Freedom from recurrence in less (ADI ≤ 50) vs. more (ADI > 50) deprived neighborhoods was 99.47% vs. 99.61% at 6 years, respectively (p = 0.2). Freedom from recurrence in patients with a CCI of 0 (low comorbidity burden) vs. a CCI of ≥7 (high comorbidity burden) was 99.67% vs. 99.27% at 6 years, respectively (p = 0.9). Conclusions: This study demonstrates that there are no significant effects of SES or comorbidity burden on freedom from recurrence in patients with IGSRT-treated NMSC. This supports the expansion of IGSRT in deprived neighborhoods to increase access to care, and IGSRT should be a consideration even in patients with a complex comorbidity status. Full article
(This article belongs to the Special Issue Advanced Research in Imaging-Guided Cancer Therapy)
Show Figures

Figure 1

Other

Jump to: Research

26 pages, 4317 KiB  
Systematic Review
Molecular-Targeted Fluorescence Lymph Node Imaging Could Play a Clinical Role in the Surgical Setting: A Systematic Review
by Bo E. Zweedijk, Sebastiaan W. R. Dalmeijer, Labrinus van Manen, Hidde A. Galema, Lorraine J. Lauwerends, Hamed Abbasi, Bernd Kremer, Cornelis Verhoef, Dominic J. Robinson, Sjors A. Koppes, Alexander L. Vahrmeijer, Joost R. van der Vorst, Denise E. Hilling and Stijn Keereweer
Cancers 2025, 17(8), 1352; https://doi.org/10.3390/cancers17081352 - 17 Apr 2025
Viewed by 469
Abstract
The lymphatic system plays a crucial role in the spread of solid tumors and is often the first site of metastasis, as cancer cells typically invade nearby lymph nodes (LN) before potentially spreading to other LNs through the lymphatic system and distant organs [...] Read more.
The lymphatic system plays a crucial role in the spread of solid tumors and is often the first site of metastasis, as cancer cells typically invade nearby lymph nodes (LN) before potentially spreading to other LNs through the lymphatic system and distant organs through the bloodstream [...] Full article
(This article belongs to the Special Issue Advanced Research in Imaging-Guided Cancer Therapy)
Show Figures

Figure 1

Back to TopTop